Indianapolis-based Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma company a pipeline of preclinical and clinical radioligand therapies for cancer. The purchase price is an 87% premium to Point’s closing stock price on Oct. 2, and a 68% premium to the 30-day volume-weighted average price. Shares (NASDAQ:PNT) of Point, also of Indianapolis, rose 84.9%, or $5.67, to close at $12.36 on Oct. 3.
Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatmentDALLAS, TX / ACCESSWIRE / June 15, 2023 / Nano Imrad
NEW YORK, NY / ACCESSWIRE / April 21, 2023 / Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis, and treatment remains challenging. It is a devastating disease